Literature DB >> 32187548

Cyclophilin A Prevents HIV-1 Restriction in Lymphocytes by Blocking Human TRIM5α Binding to the Viral Core.

Anastasia Selyutina1, Mirjana Persaud1, Lacy M Simons2, Angel Bulnes-Ramos1, Cindy Buffone1, Alicia Martinez-Lopez1, Viviana Scoca3, Francesca Di Nunzio3, Joseph Hiatt4, Alexander Marson5, Nevan J Krogan4, Judd F Hultquist2, Felipe Diaz-Griffero6.   

Abstract

Disruption of cyclophilin A (CypA)-capsid interactions affects HIV-1 replication in human lymphocytes. To understand this mechanism, we utilize human Jurkat cells, peripheral blood mononuclear cells (PBMCs), and CD4+ T cells. Our results show that inhibition of HIV-1 infection caused by disrupting CypA-capsid interactions is dependent on human tripartite motif 5α (TRIM5αhu), showing that TRIM5αhu restricts HIV-1 in CD4+ T cells. Accordingly, depletion of TRIM5αhu in CD4+ T cells rescues HIV-1 that fail to interact with CypA, such as HIV-1-P90A. We found that TRIM5αhu binds to the HIV-1 core. Disruption of CypA-capsid interactions fail to affect HIV-1-A92E/G94D infection, correlating with the loss of TRIM5αhu binding to HIV-1-A92E/G94D cores. Disruption of CypA-capsid interactions in primary cells has a greater inhibitory effect on HIV-1 when compared to Jurkat cells. Consistent with TRIM5α restriction, disruption of CypA-capsid interactions in CD4+ T cells inhibits reverse transcription. Overall, our results reveal that CypA binding to the core protects HIV-1 from TRIM5αhu restriction.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD4(+) T cells; CypA; HIV-1; TRIM5α(hu); capsid; core; cyclosporine A; restriction; reverse transcription; uncoating

Mesh:

Substances:

Year:  2020        PMID: 32187548      PMCID: PMC7363000          DOI: 10.1016/j.celrep.2020.02.100

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  62 in total

1.  Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid.

Authors:  T R Gamble; F F Vajdos; S Yoo; D K Worthylake; M Houseweart; W I Sundquist; C P Hill
Journal:  Cell       Date:  1996-12-27       Impact factor: 41.582

2.  Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1.

Authors:  Matthew Stremlau; Byeongwoon Song; Hassan Javanbakht; Michel Perron; Joseph Sodroski
Journal:  Virology       Date:  2006-04-27       Impact factor: 3.616

3.  Transportin-1 binds to the HIV-1 capsid via a nuclear localization signal and triggers uncoating.

Authors:  Juliette Fernandez; Anthony K Machado; Sébastien Lyonnais; Célia Chamontin; Kathleen Gärtner; Thibaut Léger; Corinne Henriquet; Camille Garcia; Débora M Portilho; Martine Pugnière; Laurent Chaloin; Delphine Muriaux; Yohei Yamauchi; Mickaël Blaise; Sébastien Nisole; Nathalie J Arhel
Journal:  Nat Microbiol       Date:  2019-10-14       Impact factor: 17.745

4.  Flexible use of nuclear import pathways by HIV-1.

Authors:  KyeongEun Lee; Zandrea Ambrose; Thomas D Martin; Ilker Oztop; Alok Mulky; John G Julias; Nick Vandegraaff; Joerg G Baumann; Rui Wang; Wendy Yuen; Taichiro Takemura; Kenneth Shelton; Ichiro Taniuchi; Yuan Li; Joseph Sodroski; Dan R Littman; John M Coffin; Stephen H Hughes; Derya Unutmaz; Alan Engelman; Vineet N KewalRamani
Journal:  Cell Host Microbe       Date:  2010-03-18       Impact factor: 21.023

5.  Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1.

Authors:  David M Sayah; Elena Sokolskaja; Lionel Berthoux; Jeremy Luban
Journal:  Nature       Date:  2004-07-07       Impact factor: 49.962

6.  Genome-scale RNAi screen for host factors required for HIV replication.

Authors:  Honglin Zhou; Min Xu; Qian Huang; Adam T Gates; Xiaohua D Zhang; John C Castle; Erica Stec; Marc Ferrer; Berta Strulovici; Daria J Hazuda; Amy S Espeseth
Journal:  Cell Host Microbe       Date:  2008-10-30       Impact factor: 21.023

7.  Nup153 Unlocks the Nuclear Pore Complex for HIV-1 Nuclear Translocation in Nondividing Cells.

Authors:  Cindy Buffone; Alicia Martinez-Lopez; Thomas Fricke; Silvana Opp; Marco Severgnini; Ingrid Cifola; Luca Petiti; Stella Frabetti; Katarzyna Skorupka; Kaneil K Zadrozny; Barbie K Ganser-Pornillos; Owen Pornillos; Francesca Di Nunzio; Felipe Diaz-Griffero
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

8.  A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction.

Authors:  Melvyn W Yap; Sébastien Nisole; Jonathan P Stoye
Journal:  Curr Biol       Date:  2005-01-11       Impact factor: 10.834

9.  Dynamics and regulation of nuclear import and nuclear movements of HIV-1 complexes.

Authors:  Ryan C Burdick; Krista A Delviks-Frankenberry; Jianbo Chen; Sanath K Janaka; Jaya Sastri; Wei-Shau Hu; Vinay K Pathak
Journal:  PLoS Pathog       Date:  2017-08-21       Impact factor: 6.823

10.  A cyclophilin homology domain-independent role for Nup358 in HIV-1 infection.

Authors:  Anne M Meehan; Dyana T Saenz; Rebekah Guevera; James H Morrison; Mary Peretz; Hind J Fadel; Masakazu Hamada; Jan van Deursen; Eric M Poeschla
Journal:  PLoS Pathog       Date:  2014-02-20       Impact factor: 6.823

View more
  34 in total

1.  Cell Type-Dependent Escape of Capsid Inhibitors by Simian Immunodeficiency Virus SIVcpz.

Authors:  Augustin Penda Twizerimana; Rachel Scheck; Daniel Becker; Zeli Zhang; Marianne Wammers; Leandro Avelar; Marc Pflieger; Dieter Häussinger; Thomas Kurz; Holger Gohlke; Carsten Münk
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

2.  HIV-1 mutants that escape the cytotoxic T-lymphocytes are defective in viral DNA integration.

Authors:  Muthukumar Balasubramaniam; Benem-Orom Davids; Alex Bryer; Chaoyi Xu; Santosh Thapa; Jiong Shi; Christopher Aiken; Jui Pandhare; Juan R Perilla; Chandravanu Dash
Journal:  PNAS Nexus       Date:  2022-05-20

Review 3.  Novel therapeutic strategies for chronic hepatitis B.

Authors:  Sandra Phillips; Ravi Jagatia; Shilpa Chokshi
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

Review 4.  Visualizing HIV-1 Capsid and Its Interactions with Antivirals and Host Factors.

Authors:  Morganne Wilbourne; Peijun Zhang
Journal:  Viruses       Date:  2021-02-04       Impact factor: 5.818

5.  Dysregulation of the mevalonate pathway during SARS-CoV-2 infection: An in silico study.

Authors:  Juan Luis Gomez Marti; Alan Wells; Adam M Brufsky
Journal:  J Med Virol       Date:  2020-12-29       Impact factor: 20.693

6.  Intrinsic curvature of the HIV-1 CA hexamer underlies capsid topology and interaction with cyclophilin A.

Authors:  Tao Ni; Samuel Gerard; Gongpu Zhao; Kyle Dent; Jiying Ning; Jing Zhou; Jiong Shi; Jordan Anderson-Daniels; Wen Li; Sooin Jang; Alan N Engelman; Christopher Aiken; Peijun Zhang
Journal:  Nat Struct Mol Biol       Date:  2020-08-03       Impact factor: 15.369

7.  Daxx Inhibits HIV-1 Reverse Transcription and Uncoating in a SUMO-Dependent Manner.

Authors:  Sarah Maillet; Juliette Fernandez; Mathilde Decourcelle; Khadija El Koulali; Fabien P Blanchet; Nathalie J Arhel; Ghizlane Maarifi; Sébastien Nisole
Journal:  Viruses       Date:  2020-06-11       Impact factor: 5.048

Review 8.  The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus Infections.

Authors:  Paulina Glowacka; Lidia Rudnicka; Olga Warszawik-Hendzel; Mariusz Sikora; Mohamad Goldust; Patrycja Gajda; Anna Stochmal; Leszek Blicharz; Adriana Rakowska; Malgorzata Olszewska
Journal:  Biology (Basel)       Date:  2020-07-28

9.  Mutational resilience of antiviral restriction favors primate TRIM5α in host-virus evolutionary arms races.

Authors:  Michael Emerman; Harmit S Malik; Jeannette L Tenthorey; Candice Young; Afeez Sodeinde
Journal:  Elife       Date:  2020-09-15       Impact factor: 8.140

10.  A non-canonical role for the autophagy machinery in anti-retroviral signaling mediated by TRIM5α.

Authors:  Bhaskar Saha; Devon Chisholm; Alison M Kell; Michael A Mandell
Journal:  PLoS Pathog       Date:  2020-10-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.